Search results
Showing 151 to 200 of 1516 results for patients and public
Find out more about NICE technology appraisals advisory committee D members
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
In development Reference number: GID-TA11373 Expected publication date: TBC
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy
In development Reference number: GID-HTE10086 Expected publication date: 15 September 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: 22 April 2026
Read the biographies of our medical technologies advisory committee members.
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
In development Reference number: GID-TA11484 Expected publication date: TBC
Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)
Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.
View recommendations for HTG85Show all sections
Sections for HTG85
Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.
View recommendations for HTG105Show all sections
Sections for HTG105
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development Reference number: GID-MT599 Expected publication date: TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: TBC
This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Making a positive impact: people and communities network case studies
Making a positive impact: NICE people and communities network case studies
Making a positive impact: people and communities network case studies
Making a positive impact: NICE people and communities network case studies
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Biographies and registered interests for members of the Technology Appraisal Committee C
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Cyanoacrylate instillation for occlusion of parotid sinuses (HTG20)
Evidence-based recommendations on cyanoacrylate instillation for occlusion of parotid sinuses. This involves injecting a solution of lipiodiol and cyanoacrylate via the sinus into the parotid gland, sealing the sinus.
View recommendations for HTG20Show all sections
Sections for HTG20
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence
In development Reference number: GID-HTE10069 Expected publication date: 11 August 2026
In development Reference number: GID-TA11023 Expected publication date: TBC
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Evidence-based recommendations on insertion of hydrogel keratoprosthesis. This involves putting an artificial cornea into place in a pocket made in the front part of the eye.
View recommendations for HTG42Show all sections
Sections for HTG42
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
same mission: helping practitioners and commissioners get the best care to patients fast, while ensuring value for the taxpayer. To...
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
In development Reference number: GID-TA11115 Expected publication date: TBC
High dose rate brachytherapy for carcinoma of the cervix (HTG104)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for HTG104Show all sections
Sections for HTG104
Vagus nerve stimulation for refractory epilepsy in children (HTG25)
Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.
View recommendations for HTG25Show all sections
Sections for HTG25
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
Biographies and registered interests for members of the Technology Appraisal Committee C
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
We want you to help NICE to develop our guidance for NHS and care services.
We want you to help NICE to develop our guidance for NHS and care services.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Balloon angioplasty of pulmonary vein stenosis in infants (HTG46)
Evidence-based recommendations on balloon angioplasty of pulmonary vein stenosis in infants. This involves involves inflating a balloon in the narrow section of the pulmonary vein to widen the area so blood can flow through more easily.
View recommendations for HTG46Show all sections
Sections for HTG46
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.
View recommendations for HTG41Show all sections
Sections for HTG41
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.
View recommendations for HTG44Show all sections
Sections for HTG44
This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal
We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.